CONDUCTIVE POLYMERIC COATING WITH OPTIONAL BIOBENEFICIAL TOPCOAT FOR A MEDICAL LEAD

• US 20070239245A1
• Filed: 03/29/2006
• Published: 10/11/2007
• Est. Priority Date: 03/29/2006
• Status: Active Grant

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Jiang, Xiangchun, Waszczuk, Piotr, Borgaonkar, Harshad, Cooke, Daniel
• Granted Patent: US 7,881,808 B2
• Time in Patent Office: Days
• US Class Current: 607/121
• CPC Class Codes: A61N 1/05 for implantation or insertion into the body, e.g. heart electrode A61N1/06 takes precedence
• CPC Class Codes: A61N 1/0565 Electrode heads
• CPC Class Codes: A61N 1/0568 with drug delivery

Abstract

A cardiac lead comprising a lead body extending from a proximal end portion to a distal end portion; a cardiac electrode disposed along the lead body; and a coating associated with at least a portion of the electrode, wherein the coating comprises a conductive polymer.

Claims

1. A cardiac lead comprising:

a lead body extending from a proximal end portion to a distal end portion;

a cardiac electrode disposed along the lead body; and

a coating associated with at least a portion of the electrode,

wherein the coating comprises at least one of sulfonated polytetrafluorethylene, poly(3,4-ethylenedioxythiophene)poly(styrenesulfonate) or polypyrrole polystyrene sulfonate.

2. The lead of claim 1, wherein the coating comprises sulfonated polytetrafluorethylene.

3. The lead of claim 1, wherein the coating comprises poly (3,4-ethylenedioxythiophene)poly(styrenesulfonate).

4. The lead of claim 1, wherein the coating comprises polypyrrole polystyrene sulfonate.

5. The lead of claim 1, further comprising a topcoat of phosphorylcholine (PC), polyvinylpyrrolidone (PVP), poly(vinyl alcohol) (PVA), hyaluranic acid (HA), polyactive or a combination thereof.

6. The lead of claim 1, further comprising at least one therapeutic agent.

7. The lead of claim 6, wherein the therapeutic agent is mixed in the coating.

8. The lead of claim 6, wherein the therapeutic agent is on top of or under the coating.

9. The lead of claim 6, wherein the therapeutic agent comprises an anti-inflammatory agent, anti-proliferative agent, anti-arrhythmic agent, anti-migratory agent, anti-neoplastic agent, antibiotic agent, anti-restenotic agent, anti-coagulation agent, anti-clotting agent, anti-thrombogenic agent, immunosuppressive agent, steroid or a combination thereof.

10. The lead of claim 6, wherein the therapeutic agent comprises paclitaxel, clobetasole, rapamycin, everolimus, tacrolimus, actinomycin-D, dexamethasone, vitamin E, mycophenolic acid, cyclosporin, beclomethasone or a combination thereof.

11. A method comprising:

covering a portion of a cardiac electrode with a coating,

wherein the coating comprising at least one conductive matrix polymer layer comprising sulfonated polytetrafluorethylene, poly(3,4-ethylenedioxythiophene)poly(styrenesulfonate), polypyrrole polystyrene sulfonate, or a combination thereof; and

delivering the cardiac lead to a site of implantation.

12. The method of claim 11, further comprising contacting the matrix polymer layer with a therapeutic agent.

13. The method of claim 11, further comprising contacting the matrix polymer layer with a topcoat layer.

14. The method of claim 13, further comprising contacting the topcoat layer with a therapeutic agent.

15. The method of claim 11, wherein the coating is applied to a thickness of about 25 to about 100 microns.

16. The method of claim 11, wherein the coating is applied by spraying, dipping, drop coating, sputtering, brushing or a combination thereof.